Madueke-Laveaux Obianuju Sandra, Ciebiera Michal, Al-Hendy Ayman
Department of Obstetrics and Gynecology, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw, Poland.
F S Rep. 2022 Nov 21;4(2 Suppl):46-50. doi: 10.1016/j.xfre.2022.11.008. eCollection 2023 Jun.
Treatment of heavy menstrual bleeding associated with uterine fibroids (UF) is evolving. Historically, treatment options were limited to predominantly invasive surgery; today, conservative and novel oral medical treatments are widely available for use with significant efficacy. This evolution was directly driven by our improved understanding of UF pathophysiology. Specifically, our recognition of the hormone-mediated pathway in UF development and growth laid the framework for using GnRH agonist analogs in treating UF. In this report, we explore the use of GnRH analogs in the treatment of heavy menstrual bleeding associated with UF in phases. We review historical perspectives, discuss the development and use of aternatives to GnRH analogs, a period we refer to as the "Dark Ages" of GnRH analogs, we then provide an overview of the later years and present-day use of GnRH analogs and discuss opportunities for future directions.
与子宫肌瘤(UF)相关的月经过多的治疗方法正在不断发展。从历史上看,治疗选择主要局限于侵入性手术;如今,保守的新型口服药物治疗广泛可用且疗效显著。这种演变直接得益于我们对子宫肌瘤病理生理学的深入理解。具体而言,我们对激素介导的子宫肌瘤发生和生长途径的认识为使用促性腺激素释放激素(GnRH)激动剂类似物治疗子宫肌瘤奠定了框架。在本报告中,我们分阶段探讨GnRH类似物在治疗与子宫肌瘤相关的月经过多中的应用。我们回顾历史观点,讨论GnRH类似物替代疗法的发展和使用情况,我们将这一时期称为GnRH类似物的“黑暗时代”,然后概述GnRH类似物的后期及当前使用情况,并讨论未来的发展方向。